Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 352

1.

Time course of asymmetric dimethylarginine and symmetric dimethylarginine levels after successful renal transplantation.

Claes KJ, Bammens B, Kuypers DR, Meijers B, Naesens M, Sprangers B, Vanrenterghem Y, Lerut E, de Loor H, Evenepoel P.

Nephrol Dial Transplant. 2014 Oct;29(10):1965-72. doi: 10.1093/ndt/gfu219. Epub 2014 Jun 23.

PMID:
24957811
2.

Postimplantation X-ray parameters predict functional catheter problems in peritoneal dialysis.

Bammens B, Peeters D, Jaekers J, Claes KJ, Evenepoel P, Kuypers D, Meijers B, Naesens M, Vanrenterghem Y, Monbaliu D.

Kidney Int. 2014 Nov;86(5):1001-6. doi: 10.1038/ki.2014.203. Epub 2014 Jun 18.

PMID:
24940799
3.

Intrarenal resistive index after renal transplantation.

Naesens M, Heylen L, Lerut E, Claes K, De Wever L, Claus F, Oyen R, Kuypers D, Evenepoel P, Bammens B, Sprangers B, Meijers B, Pirenne J, Monbaliu D, de Jonge H, Metalidis C, De Vusser K, Vanrenterghem Y.

N Engl J Med. 2013 Nov 7;369(19):1797-806. doi: 10.1056/NEJMoa1301064.

4.

Serum concentrations of p-cresyl sulfate and indoxyl sulfate, but not inflammatory markers, increase in incident peritoneal dialysis patients in parallel with loss of residual renal function.

Viaene L, Meijers BK, Bammens B, Vanrenterghem Y, Evenepoel P.

Perit Dial Int. 2014 Jan-Feb;34(1):71-8. doi: 10.3747/pdi.2012.00276. Epub 2013 Oct 31.

5.

Post-streptococcal glomerulonephritis: not an extinct disease!

Demuynck M, Lerut E, Kuypers D, Evenepoel P, Claes K, Naesens M, Meijers B, Vanrenterghem Y, Bammens B.

Acta Clin Belg. 2013 May-Jun;68(3):215-7.

PMID:
24156223
6.

Long-term exposure to belatacept in recipients of extended criteria donor kidneys.

Charpentier B, Medina Pestana JO, Del C Rial M, Rostaing L, Grinyó J, Vanrenterghem Y, Matas A, Zhang R, Mühlbacher F, Pupim L, Florman S.

Am J Transplant. 2013 Nov;13(11):2884-91. doi: 10.1111/ajt.12459. Epub 2013 Sep 18.

7.

Impact of CYP3A5 genotype on tacrolimus versus midazolam clearance in renal transplant recipients: new insights in CYP3A5-mediated drug metabolism.

de Jonge H, de Loor H, Verbeke K, Vanrenterghem Y, Kuypers DR.

Pharmacogenomics. 2013 Sep;14(12):1467-80. doi: 10.2217/pgs.13.133.

PMID:
24024898
8.

The predictive value of kidney allograft baseline biopsies for long-term graft survival.

De Vusser K, Lerut E, Kuypers D, Vanrenterghem Y, Jochmans I, Monbaliu D, Pirenne J, Naesens M.

J Am Soc Nephrol. 2013 Nov;24(11):1913-23. doi: 10.1681/ASN.2012111081. Epub 2013 Aug 15.

9.

Aortic calcifications and arterial stiffness as predictors of cardiovascular events in incident renal transplant recipients.

Claes KJ, Heye S, Bammens B, Kuypers DR, Meijers B, Naesens M, Vanrenterghem Y, Evenepoel P.

Transpl Int. 2013 Oct;26(10):973-81. doi: 10.1111/tri.12151. Epub 2013 Jul 19.

PMID:
23870026
10.

Renal clearance and intestinal generation of p-cresyl sulfate and indoxyl sulfate in CKD.

Poesen R, Viaene L, Verbeke K, Claes K, Bammens B, Sprangers B, Naesens M, Vanrenterghem Y, Kuypers D, Evenepoel P, Meijers B.

Clin J Am Soc Nephrol. 2013 Sep;8(9):1508-14. doi: 10.2215/CJN.00300113. Epub 2013 Jun 27.

11.

Reasons for dose reduction of mycophenolate mofetil during the first year after renal transplantation and its impact on graft outcome.

Vanhove T, Kuypers D, Claes KJ, Evenepoel P, Meijers B, Naesens M, Vanrenterghem Y, Cornelis T, Bammens B.

Transpl Int. 2013 Aug;26(8):813-21. doi: 10.1111/tri.12133. Epub 2013 Jun 10.

PMID:
23746202
12.

Combined kidney and intestinal transplantation in patients with enteric hyperoxaluria secondary to short bowel syndrome.

Ceulemans LJ, Nijs Y, Nuytens F, De Hertogh G, Claes K, Bammens B, Naesens M, Evenepoel P, Kuypers D, Vanrenterghem Y, Monbaliu D, Pirenne J.

Am J Transplant. 2013 Jul;13(7):1910-4. doi: 10.1111/ajt.12305. Epub 2013 Jun 3.

13.

Improved adherence to tacrolimus once-daily formulation in renal recipients: a randomized controlled trial using electronic monitoring.

Kuypers DR, Peeters PC, Sennesael JJ, Kianda MN, Vrijens B, Kristanto P, Dobbels F, Vanrenterghem Y, Kanaan N; ADMIRAD Study Team.

Transplantation. 2013 Jan 27;95(2):333-40. doi: 10.1097/TP.0b013e3182725532.

PMID:
23263559
14.

Renal cell carcinoma in the allograft: what is the role of polyomavirus?

Neirynck V, Claes K, Naesens M, De Wever L, Pirenne J, Kuypers D, Vanrenterghem Y, Poppel HV, Kabanda A, Lerut E.

Case Rep Nephrol Urol. 2012 Jul;2(2):125-34. doi: 10.1159/000341917. Epub 2012 Sep 5.

15.

Chronic histological damage in early indication biopsies is an independent risk factor for late renal allograft failure.

Naesens M, Kuypers DR, De Vusser K, Vanrenterghem Y, Evenepoel P, Claes K, Bammens B, Meijers B, Lerut E.

Am J Transplant. 2013 Jan;13(1):86-99. doi: 10.1111/j.1600-6143.2012.04304.x. Epub 2012 Nov 8.

16.

In vivo CYP3A4 activity, CYP3A5 genotype, and hematocrit predict tacrolimus dose requirements and clearance in renal transplant patients.

de Jonge H, de Loor H, Verbeke K, Vanrenterghem Y, Kuypers DR.

Clin Pharmacol Ther. 2012 Sep;92(3):366-75. doi: 10.1038/clpt.2012.109. Epub 2012 Aug 8.

PMID:
22871995
17.

A multicenter, randomized, double-blind study comparing different FK778 doses (manitimus) with tacrolimus and steroids vs. MMF with tacrolimus and steroids in renal transplantation.

Wlodarczyk Z, Vanrenterghem Y, Krämer BK, Squifflet JP, Ostrowski M.

BMC Nephrol. 2012 Jul 26;13:68. doi: 10.1186/1471-2369-13-68.

18.

Evidence in favor of a severely impaired net intestinal calcium absorption in patients with (early-stage) chronic kidney disease.

Viaene L, Meijers BK, Vanrenterghem Y, Evenepoel P.

Am J Nephrol. 2012;35(5):434-41. doi: 10.1159/000338299. Epub 2012 Apr 23.

PMID:
22538635
19.

Daytime rhythm and treatment-related fluctuations of serum phosphorus concentration in dialysis patients.

Viaene L, Meijers B, Vanrenterghem Y, Evenepoel P.

Am J Nephrol. 2012;35(3):242-8. doi: 10.1159/000336308. Epub 2012 Feb 18.

PMID:
22353750
20.

Three-year outcomes from BENEFIT-EXT: a phase III study of belatacept versus cyclosporine in recipients of extended criteria donor kidneys.

Pestana JO, Grinyo JM, Vanrenterghem Y, Becker T, Campistol JM, Florman S, Garcia VD, Kamar N, Lang P, Manfro RC, Massari P, Rial MD, Schnitzler MA, Vitko S, Duan T, Block A, Harler MB, Durrbach A.

Am J Transplant. 2012 Mar;12(3):630-9. doi: 10.1111/j.1600-6143.2011.03914.x. Epub 2012 Feb 2.

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Loading ...
Write to the Help Desk